Drugging the DNA damage response in the clinic: going beyond PARP.
Torrado C, Gonzalez-Ortiz A, Xavier CB, Tan HN, Ngoi NYL, Yap TA.
Torrado C, et al.
Expert Rev Anticancer Ther. 2026 Jan;26(1):43-58. doi: 10.1080/14737140.2025.2575825. Epub 2025 Oct 25.
Expert Rev Anticancer Ther. 2026.
PMID: 41086259
Review.
This review summarizes preclinical and clinical data on next-generation DDR inhibitors, including agents targeting ATR, ATM, APE1, DNA-PK, WEE1, CHK1/2, CDC7, PLK4, PKMYT1, Poltheta, USP1, PARG, WRN, and ALC1. It discusses mechanistic rationale, clinical activity, and safe …
This review summarizes preclinical and clinical data on next-generation DDR inhibitors, including agents targeting ATR, ATM, APE1, DNA-PK, W …